PODD - Earnings call transcript Q3 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Third Quarter of 2020 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Deborah Gordon, Vice President, Investor Relations.

Deborah Gordon

you call. us thank quarter Insulet's and earnings XXXX afternoon, for for joining third Good today Shacey and me Wayde With are McMillan, Officer; Chief Executive and Executive Vice President Chief Officer. Petrovic, Financial President and of of is the release and also the and fourth available replay our XXXX full and section third press this archived in discussing be The on our will year website quarter quarter our website. results call XXXX IR guidance

made differ forward-looking statements Insulet to be that inform of expectations. the Before course our contained inherent to you this during We of cautionary we refer begin, would of explanation in certain the limitations the SEC I forward-looking like statements. that and from ask by call for may filings detailed such statements please could you materially current a

as measures will interested supplemental helpful and to and growth We adjusted performance in analysts the period foreign namely, and with performance discuss measure is measures revenue investors, to they operating other believe which These financial from our with also our that of excluding as respect performance, to our we comparative are non-GAAP a aligned constant effect what revenue, period. of operating management currency uses parties EBITDA assessing measures exchange.

that, Additionally, will be will on unless dollar be turn regarding and otherwise changes call revenue stated, basis. the Shacey. growth rates a with all and on And basis, percentage I'll financial over commentary currency all a to year-over-year constant

Shacey Petrovic

commitment call rest and open and will imperatives, many then Wayde we future. The We and on challenging the progress and innovation growth this financial On pipeline the call, about results all you questions. our recurring this our today's OmniPod's team. Insulet Good form year, of resilience has our for who then cared the Together, revenue our your afternoon, despite revenue for in us. demonstrates another of on users the times. business. discuss team our delivered reasons everyone, of strategic third we've remain of and differentiated progress support, advanced unprecedented our factor I'll We challenging we'll Thanks, quarter the achieved XX%. remarkable outlook to our model, business our and the you quarter thank need excited joining made for Deb. environment, our durability are of with update and aspects

and lines, U.S. each revenue another product international OmniPod achieved record quarter. Our

now fifth customer New XX% we revenue expect stronger year our consecutive expected, starts were deliver growth of than and pandemic. the to despite

the our XXXX of finish the also start year. at expectations to We expect pre-COVID above

opportunity better also building life expand bring access the While awareness over outcomes delivering just and with we to grow long-term. and performance, strong and there quality game-changing serve, diabetes, significantly consumer-oriented could who In markets are benefit approximately OmniPod. XX market enormous currently improved in This from and our adoption million into innovations to we drive living people are technologies market. we move the insulin-dependent as will a to of market with growing foundation new geographies, our our

quality growth long-term increasing the manufacturing the supported will our – required be produce to products, highest Our highest by margins. expertise gross while

diabetes We advantages us lives access enduring years build come. enable these to and start are each for will expanding people improve areas awareness. with in investing that of of the to with to I'll many

or easily available regardless We of are age, establishing market access payer. diabetes of so type OmniPod is

one-time a Benefit training customers the Co-pays offers swift. access pharmacy come is U.S. quick are cost. effective. low and with experience. simple large don't channel an and virtual And Our onboarding through are unusually checks

and now providers. virtual by embrace users challenges, pushed While preferred also COVID-XX training, has has is presented it to us which

daily injection in capabilities scale business. customers the unique of our were to we attracted ease-of-use our We as Approximately value to XX% users expect multiple to OmniPod's new these developed continue form newly third and provide factor. quarter

Additionally, success of a X ago, users MDI pump. last and start to United had a trial upfront and the covered OmniPod we we quarter. approximately pay DASH Type broad By no coverage locked with XX% have on into or an a the Fueling unparalleled QX, simplicity launched period. were pharmacy secured lives up OmniPod customers pharmacy, built large four-year OmniPod to in XX for OmniPod from in Type try DASH. DASH's of costs grown They XX% for U.S. months our is the and awareness new of the can get With insulin OmniPod longer free lock-in has with X, end of one-third DASH. Since access States. MDI contract no

September We and a a outcomes are time ton. learning and improved access broad life progress diabetes. down with to of the barriers on be knocking enabling to bring launch small-scale pharmacy and establishing quality market been the pilot our to to the in thrilled was people We through advertising have In launched channel, right pilot. more OmniPod direct-to-consumer

customers. know we performance raise to as are retention is our and awareness DTC delighted be strong to monitoring adoption, key we to of such are increased such know key we invest and and is a While rates in We DTC-generated explore this growing awareness, still position area. metrics, conversion lead working to

first only the OmniPod simplicity beat has pipeline. market system on with tubeless like a been team today. OmniPod world's system has controlled world a personal AID pandemic, X our challenged is not fully the freedom, our advancing the in and other technology with one X, consumer give wearable innovation missed While and our mobile customers integration the no user's we by With will phone. our

applications technology transformative our Type X is launch plus, for of And X step. platform OmniPod in seven diabetes a users marks our aged delivery first insulin with of initial variety segments. potential automated Our

it explore impact make lives prove clinical diabetes. will studies be in the to will the investing market the X's people about utility then we segments. first excited are on time, Over We and in market and with OmniPod of more in

pivotal this year. half and X our recently We remain OmniPod on in first launch completed to trial are coming thrilled of track to the have

us FDA trial to will prepares will also extension for of all pivotal the value additional data team X. proposition provide and beyond innovations on with our They future critical and our have help inform virtually clinicians. data submission, OmniPod payers with This into participants product OmniPod transitioned a with While X's remain support phase.

share are our And do clinical excited results. We to best ATTD delayed, given to has been the evaluating are alternative we so.

one two X make participants available we Our X off with demographic, XX pivotal kicked OmniPod are this down ranks study with and delighted within to age pre-school all to is under product. olds OmniPod study six way to number to on OmniPod have pivotal our year two.

this the caregivers. XXXX the and for have their goal by young Our population end is of to indication expanded

XX each FDA's September, Type two the wearing approximately we following of X for enrollment. study include study OmniPod participants, Additionally, This clinical acceptance X our protocol, will began months. XX to in feasibility

AID a we there an X learn from growing X market appropriate As more our Type is large we base, for Type know system. user

are month products provide clinical We simple exceptionally system Type in grow in will AID pay-as-you-go important confident learnings. and OmniPod's to OmniPod the result our developing us great an expect factor, the X our form for value our early use and will position population, Type pod users. experience uniquely work we X pharmacy model

our products. submission X's on and prepare for progress we also OmniPod commercial we future While making are launch,

that our generations better technology CGM Type among is the delivery Abbott need recognize X needs. adoption with and products OmniPod Type Dexcom CGM diabetes solutions. meet advancing We users. are of and to way rapidly X users helping they meaningfully And is who awareness for and are paving insulin collaborations these raising of

advance under exciting next integration with simplicity ease-of-use. sensors, our addition iOS. work algorithm our our with compatible and X have continue expand generation In to lead way we we to make OmniPod to to in And

in international markets. Now, turning to our progress our

European in we full seen commercial rollout the OmniPod have DASH. announced We markets. gradual of in a recovery September, And our

a the and Our customers done remarkable preparing teams our support markets this have product. to loving our are job launch,

we each Europe our of capabilities to to early start leverage Now are the start OmniPod on efforts, and a expansion announced and September, and existing distributor markets XXX% teams We're taking expansion new we of in deliberate five DASH. on international XXXX. as relationships. by strong we our market In build in our geographic track our our new enter approach customers

to significantly global market. time expanded take broaden presence, our our the will term, will our addressable longer it total footprint increase While over

operational the capacity for the demand growing we both are Finally, OmniPod, In turning in increasing meet excellence. China. order to United to States and

our produce are with of the manufacturing We automated we are first ramp next highly we third two And expect year. considerable of completion line installation, our making sellable product lines. U.S. progress nearing which will

In allowing the in capacity team summary, manufacturing world our contract another and These chain the investment of China, supplier and pandemic. long-term the in operations local to quickly manufacturer highly global made experienced base leverage increased global have we and meet products. over strengthen investments that demand challenged to and impact remains for scale. redundancy our us We to have supply our the ensure also the global with an

However, taking OmniPod, to our enhance of the appropriate capabilities. delivered and addressable insulation financial and strong markets compelling recurring execution the provide benefits uniqueness and performance, Insulet. the of grow operational global our we of revenue team for our expand our We manufacturing and outstanding the model pipeline, significant and durability are our steps innovation

I lives remain our improving first importantly, Our turn now will And team living to OmniPod strong is the of toward over half the focused with momentum XXXX. launch finishing we of as we and sustaining the Wayde. diabetes. X on year people on in move of call the most focused

Wayde McMillan

Thanks, Shacey.

maintained again performance, record our customers our lines. Our team. revenue We've of due growth, third of Insulet continuation as track execution double-digit largely record commitment global a strong to we and performance, of quarter for quarterly once our the diabetes solid loyal marked our delivered and product revenue a including

We of to strategic the delivering advancing and improve lives on diabetes. are with our our mission imperatives people steadily

revenue and execution, we we a expect start year customer see third strong quarter an and to headwind our began XXXX. Despite and on Turning compounding which outperformance our impact our expectations result third growth QX, to of XX%, to revenue and this pre-COVID OmniPod of continued quarters. OmniPod our which above Total the revenue XX% In new our both of we'll year-to-date delivery above exceeded million $X starts pandemic also negatively $X ahead In of million the than finished OmniPod our our million new It and total smaller XX%, impacted range. range. delivered the major driver financial with results. of at $X growth was our of was half growth business, a second full the creates guidance our in This the We year XXXX guidance guidance guidance and for as revenue, was customer impact our our headwind the expected. a fourth see global results the range. expectations. into above first starts. exceed total continue in Drug ahead third quarter growth to quarter which was expectations we now of

that the the beginning XX%. would XX% to our by pandemic expect We lower of year expectations

impact were results and favorable with combined XX%. in Our regions U.S. both slightly than less international the the

and international in Additionally, sequentially. stable both for half had significant total the QX and resulting sequential impact were U.S. Attrition versus QX. the in improvements OmniPod utilization of approximately

OmniPod by levels, product X guidance QX in of million Looking built the revenue to mainly a approximate an U.S. XX% channel first the the of channel inventory range pandemic. estimated XX%, year, of to decrease XX%. half due line, exceeding revenue partially grew offsetting headwind inventory our included distributor in

where starts. PDM our driven starts. OmniPod shift charge. our to total than to XX%. to DASH with base, mix of customer primarily million amount better OmniPod guidance range by X the estimated similar X% experienced in increased increased including channel, U.S. In was volume from And the quarter in of the compared to compared increased was XX% pharmacy increased new inventory through revenue the to DASH XX% DASH adoption to growth the current XX% our million Channel the strong related premium XX%, over we an the the Similar and was to due at our Drug overachievement OmniPod volume. by benefit our of grew of we to no guidance stocking the and to approximately X U.S. driven of to growth due customers primarily estimated we customer expected further quarter, International of grew environment. to our on channel to XX% XX% Our XXXX. QX, the the range provide drove expansion distributor of new forecast QX pharmacy third revenue of delivery OmniPod shipments DASH partners' customer orders to

as ramp up mix. Turning well the automated volume gross as product favorable XX expansion our to pharmacy U.S. XX%, expectations. delivered line of through our implemented Also mix was lines improving newly channel. margin. performance to as revenue the Key we basis contributing exceeding points, We manufacturing from gross drivers the of our our included higher shift margin favorable

While costs basis was slightly expenses a it our million. from expectations the was positive by headwind of tailwind, a performance. a with dollar quarter, point primarily well marketing and foreign up for XX on revenue and given year. in basis, top-line point largely $X.X Operating were prior XX.X% as XX third quarter exchange offset due a basis increased as in revenue of percentage in lower spend percentage costs the our on strong one-time XX.X% COVID-related in as as dollar a basis EBITDA from of third the to Adjusted the clinical X. OmniPod a Expenses R&D was line

and the in benefited improvement with profitability income. from and improved leverage Our gross expense change other margins operating operations

further in debt with a raised $XXX in quarter XXXX position of in and our We our building reduce low us cash an the continue Turning cash strong million additional cost maturing We additional capital. our to we third remain imperatives. $XXX to to overall helped invest million cash ended with position The strengthens of and as and allows strategic arrangements investments. and Subsequent interest earliest cash related and our QX, type these to to of in liquidity. to cash expense. financings equipment

and primarily expansion geographic are commercial for scale to and international supply manufacturing well and product and sales operations capacity investments expansion. as R&D Our global programs, chain as force

position and with serving rapid to capital provides strong growth. and foundation for a are strengthen further positioned We drive our us uniquely by market, cash our sustainable long-term to underpenetrated growth large

to turning our revised XXXX. outlook Now for

revenue to As to above company year exceeded of raising up includes range beginning to are previous XX% of revenue that quarter and guidance to growth total XX%. our expectations of XX%, a XX% full result raising XX% of a This from third to expectations, OmniPod of we estimate. XXXX our total XX% year our revenue

execution now guidance durable start Our our annuity total line with which the testament and in pre-COVID, year a OmniPod the original our XX% revenue of to are back are for raising our of of we are international growth our XX%. our rates the growth XX%. U.S. at to XX% model for set is product And the to By resilience line, expected we to team. OmniPod, to Insulet OmniPod, raising expectations

generate will Despite year global global the starts improve year year beyond. now we pandemic difficult the XX% Although in beginning to approximately predict COVID of XXXX our of and remains to progression to new as the a business as it and probability positioned customer of diabetes estimate. our the this full for growth to create of the is uncertainties challenging or resurgence, well of well the expect the strong XXXX environment,

business increased revenue Lastly, expected resulting for drug delivery, our to we growth to our the from are X% X%, forecast from partner. updating

Turning P&L. to the the rest of

related XX%. versus safety XXXX of to to year and to to favorable efforts our COVID estimated expenditures be guide of projects raising approximately third from of or points As $X approximately $XX XXX includes This will a our spend to outperformance million we up in guidance due costs are quarter now $XX to million outlook, result headwind approximately estimated to of million. basis levels coming $X full prior mitigation the capital below million our stronger in XXXX and and expect gross margin prior due timing. year We XX%, revenue the one-time

we expansion. our and expect well next financial capital advancements strategy long-term therefore unchanged. commercial chain capacity to and support scaling to as deployment supply grow and operations and innovation remain plans And expenditures year pipeline again manufacturing in international Our capital as

a end our revenue, of XX% range. we stated in come XX% For adjusted at expect as to XXXX low to of continue previously the to full percentage year EBITDA,

guidance. fourth international expect OmniPod to starts and two grow from total as customer decline reflects to This growth quarter U.S. which to of drug XX%. of revenue revenue lower Turning expect OmniPod XX% new XX% to the growth total now related XXXX to X% delivery and company to We a XX%, to line, compounding of prior the XX%. we product By the pandemic. includes revenue reminder, to XX% XX% each quarters

strong customers, beginning QX conclusion, and QX revenue our achieved quarter XX% we in compares In the product we durable year-to-date range of despite expect to a model. on to to to of less terms new than from of the to year the XX% of global position guided customer and improve market we fourth our This speaks expectations. growth the through In differentiated to new starts XX%, the now calls. innovation impact the recurring pandemic. This power global our impact

and is strong financial position is our Our innovation pipeline sound.

momentum the as year on and enter strong finishing are we building focused We XXXX.

next conditions in turn the our end a we'll deliver XXXX to over billion mid-teens. revenue, XX% of on the market gross track the Q&A. operator remain in percentage to at targets stabilize Assuming the and income low of to With revenue operating year, of for as $X range we XX% call margin of that,

Operator

William you. from Our of first the Margaret line ahead. Kaczor [Operator Blair. from go question comes Please Thank Instructions]

Brandon Vazquez

Margaret. on Hi, is question. everyone. This for Brandon for taking Thanks the

First I the seen COVID We've that? globally. you COVID lot guide. talk just into what of kind QX on of about a resurgence headwinds could if of focus are obviously baked just Can maybe

the So stay of kind fourth as or assume does things bake getting quarter? does it the things of that we that in worse same go kind through

Wayde McMillan

start it's today, in you is It's the different Brandon. this Hey, it's with as start and obviously that because a really said. in I good a can Wayde. business one. U.S. to driver the place actually And major and international,

in year expectations but we've been we our performing U.S. well And in reminder, just highest been starts U.S. customer QX be QX the and starts. first, our the year prior pretty of close the QX about is was new talk we've QX, prior to in quite So year. and new in customer if in business, going a the beginning been the And below QX to have momentum building all-time

Type a a The X investments force. expanding a we is really DASH driving is U.S., been momentum. training. virtual building. made us. teams great and The QX. move And comp the But that in the in done our We've still of tough job have sales in early. so pay-as-you-go momentum things has still for our get then well. working business driver with got is a the commercial pharmacy primary And ramping model We've the into lot

there's So And from that result, as still starts. in offsetting are customer our of lot double-digit a guide. just we a somewhat headwinds new those positives got growth

strong for U.S., If so an a even the for QX. to customer the recovery can high countries mentioned, us as lockdown. From a The And above, going it's then few guide starts story. our to seen back it's be we pretty pretty in we've slower. close. standpoint, new going are to you going be or end a get been different recently And international has into more of

be to with launching with great because us finding gives it and for it's teams with QX still opportunity caught more is teams our to effective customers. they everybody this But speaking physicians staying their much with now, And is our DASH by really when be teams so in it's our what's a challenging. with just connect it's anticipate in great customers, different and there, do meetings surprise – are field more those to get than going them, ways an still to DASH contact timing

headwind also that momentum. but the at lots customer and us, DASH be And internationally, so of our job, there launched a high we of expanding this continue new teams and force new above newly I a end we've sales doing will better more countries. range mentioned, starts of for expansion or think into is but there we're are do made to

of a building is there this so pandemic. behind lot in And momentum

was continue so that. will headwinds end If And us ranges. assumption the see land QX to to is, that end very But impact extent of would we built guidance that it but something think extreme, our we and just And like the going I obviously we're range. of impactful high think on pretty day, predict it in of something range. the end have, to do depending can, pandemic I low at be us mean, the the into the the how we've would and how it's to anticipated difficult much that again, push the probably the should out I

Brandon Vazquez

then That's last And helpful Great. color. for really the one me.

given early internally of catalyst, kinds you it's COVID into appreciate As numbers probably but hands or – just a what are it'd back vaccine, if Thanks. for does XXXX are maybe looking of token, get forward about little XXXX, a on kind the a OmniPod you an might it COVID be widespread available same be kind that's catalysts given be needs slow normal on a to levels? of X – whether incorrect closed to get rollout vaccine, I thinking of And you specific bit to too whether how kind what pre-COVID helpful potentially loop perhaps may training the of assumption? about more that it's

Shacey Petrovic

various of vaccine our means And COVID. it expected we're teams because we with ahead macro getting and that great of what things year, tools and environment, are this in close year the see in that of the continued hoping mentioned, for throughout happen we and great think for the regardless in Wayde impact built. to I to impact of because now sort of the Brendan, it's this in of are were we've see an beginning of of did XXXX. just potential that is said the And Thanks, at had then virtual we I capabilities year the terms some and what's this what predicting to our where happens improvement managing don't going to that's and making think environment, but predict Sure. to we the training question. want XXXX, expect I what we And normalization at

that the OmniPod is everything the simple. – to that so experience and use design terms that be on spent enough can thinking users that and easily a and product to work and ensuring we that X, and designed get experience it's through product have with. the of from And In and is organizational it a successful to is onboarding kids focus much be MDI simplicity simple of system on

I to market, that internally and and to slow going get make happen product going that COVID is environment. on in There in just So that don't with anticipate of Thank we're all regardless enthusiasm of down. the the incredible the what's you. market is us to to happening macro us

Brandon Vazquez

you. Thank

Operator

Thank you.

Our next of question from the Piper comes line Please from go O'Brien Matthew ahead. Sandler.

Patrick Allen

is Good Thank everyone. for the Thank COVID you so to you. on environment. wanted Matt. for just afternoon, much This on follow-up Patrick taking little the bit I questions. a just

people You some but you April, us it that runs implemented program the further your sense that of in I till a financial program there year, participation would know be their assistance can to envision December off you. give the this And do for utilization as you any plan, or program? this really of insurance have appreciated? COBRA Thank may roll dynamic color within

Shacey Petrovic

level, say to to out product. a give while This that of little able impacting users. outsized that very were on front of more color is I'll we it's program. they But a remain a we negatively much in proud I can fashion something I'll that to think and COVID is about utilization this partners on our as and offer company ensuring assistance high very an are the Wayde Patrick. that our bit at ask Sure, that

If need the we feel to committed then we that end the is – so were And program. year. persist, may and like certainly our through this will of proud evaluate we're we program continuing intent of the

Wayde McMillan

on small have quite Patrick, numbers, And the been actually. they

been I or insurance think in but states you the people mentioned there options many the alternative other including household. has COBRA, Medicaid for in

said people had the few program quite many that, haven't the that we've seen So financial we assistance always But on having – on that and years. a several we've had program. people over

we And number is original program yet. and to of that we that had an the enhancement really so people on our haven't met this program,

we place. it's So really like given access a it to we're normal we're If them they happy more them Shacey customers been that the product point. as with again. they're have help until afford this happy current pick-up significant therapy the to in can at have continue But can't through current not their it and situation said, channels backstop than it's in,

Patrick Allen

That's DTC well, And love guys. I that know helpful more national I'd to kind you're Thank seems gauge you'll DTC to and started have efforts campaign my that follow-up. KPIs a color, program doing that you the for hear you quick that. to how is. be But more really of about limited making. successful for are thinking should the into DTC of out? efforts thanks still think the COVID we XXXX? DTC Like, X how OmniPod year with next and coming again. as round rollout that percolating you kind the some the about of impacts of into how campaign And the you about taking broader corner questions for XXXX

Shacey Petrovic

without And from on We've awareness. stuck that it's and of of clear the numbers over increased but time awareness. before to is we toe launching certainly questions the most this at this learn the Patrick, ourselves what how DTC internally. It does wanted do looking barriers – is to impact, made to digital channels And are what that's we reasons about that trial. year that is the the that customers have X we cost one we the are because Patient mean, those OmniPod the why all customers And in time funny, asking on I effective. OmniPod about wanted free upfront eliminated learn asking and any you're effective, through it's the then degree. Sure. basically messaging remember, channels, to product. couple can we're with really first we've getting what get pharmacy television. that our just really we've convert an over last driving the been actual most that into years expanding our of to is early period into a now the on are awareness impact DTC

want And patients base those so that to we make sure the the does. to our that product extent stay customer on

XXXX. what's more in and extent point determine our the then that have better support those call to learned should I increased before have give evaluating think have that that bit And view position we're our But demand. a So increase scale we're we things and and channel, next of have to the we is we on the DTC we have expanding. in what exciting pharmacy in a when by in color bringing we the of we is are plan more to kind actually the of the terms now position investment that

get channel, bit the really is to a that to DME for upfront that no more right learn getting us have of able DTC. the product, to product sort about be the in so pharmacy, and easy is exciting encouraged into through start stay walk time to to cumbersome. the onto tuned. patients onboarding process is experience, and And And cost we're patients And the and the have more

Operator

Thank you.

of from go ahead. Please the comes question Next line Morgan. Marcus Robbie from JP

Robbie Marcus

a on quarter. Congrats two really good I questions. have Great.

AID a sure First factor, lot your of sure with DASH, outpacing new of Shacey where coming I Horizon pocket. you new the do integrated hoping an is when the your it's But to was I'm of the patients X, thoughts from? us patient I'm is on solution and give of lot lower the in out it about a form a they're if it could have lot growth you has one with competitors terms status you of think of of and solution.

DASH, models, as So a coming but how the also have solution? about benefit set once competitive AID from benefit we think should the you our that's we

Shacey Petrovic

so are questions I about think those I why we're and OmniPod Yes, really think X. excited great highlight

we at new Wayde guidance could You a, see for said, our patients. end high all-time of we're in the QX, to that the back growth quarter in U.S., record the driving, be

So form factor. been frankly recovery MDI. driven being OmniPod’s has seeing are always of recovery. That great users off as is we're a of it’s, coming XX% new from

continue Type overall being we in is That and simplicity. to very driven X access attracted So to that its grow the and pharmacy is OmniPod a population Type both factor X just by users. market MDI by DASH that's and

patients are majority accessing co-pay. channel, vast and we'll think on factor for form segment OmniPod the our that the $XX a I the its out-of-pocket to continue based OmniPod than economics. in less adopt on based pharmacy Actually see of

the in It's So of and attractive today. economic. are and those so it's terms channel demand form very driving factor access very

OmniPod longer several you and we next power are patients – Dexcom have until And why X integration between the in is preferred so with or the XXXX, what a think have with excited of is first that and market, to into the next to you sensor when Dexcom the obviously, OmniPod really months few about when I people up had choose. integration are X they'll see what AID. get, highlighting can we we the sensor. is form months, choose we get And no half of know the the out

change so trends. make how not to to going predictions that's going And our on exactly I'm

and X period. in to users certainly the think coming lock-in be I users expect without or the changes more accelerator. coming is question without product, we OmniPod four-year we cost I think to what pump because onto any they terms it of can an the see adopt a product, MDI And on remember do

AID we're check box insulin excited of particular patients basically an an in X. every with So really for looking system are that system OmniPod and delivery terms in to

Robbie Marcus

particularly the Great. cases a with And especially And you’ve maybe all clearly starting since Wayde And as demonstrated unpredictability, one CFO. guidance understand to COVID-XX. in approach reason Wayde. with during very conservative a guidance again. rise stance to I you've come to I'd for say conservative good

call, numbers. us trends to quarter? destocking willing get guidance much people downward that give Thanks. think you mixed you asked metrics large would versus this help the to we conservatism volume to you us this is of understand the ask range. maybe what and you trying say of on I And some ceded can I how third think to last Just going sense that should underlying price materially in was move here. And seems a going of fairly question a conservative, different it Are say a in to far fourth quarter? in I'm But the about? I that just of get range would you versus is be out underlying you your again that some

Wayde McMillan

Robbie. Hey,

happened potential decision. First revenue back at pandemic. was of We're big this front that chose that at were brought recurring how a impacting when starts It that looked quarters, the issue very end happy But all, glad in guidance to of you the and we guidance. up QX we in really QX, compounds. we're to a one that see pandemic us and it a model we few against a going defends new in like the quarter impact, customer for

and which QX it. the quarters, over new few a compound. that in including lowest math so ends QX, they with three it's up was customer really starts our quarters, And it's

guidance QX we And that business, said, business in adding understood could putting mean, make on we people we time sure now. every I'll we are model headwind I the new mostly like a to and it by major to because our seen. starts volume. and So a volume you ground customer our that our that's held much The business business why talk additional it. is articulate have take The in conservatism, we've because our so very than wanted did we metrics of comment bigger we could business drivers and

As we start we time. and There channels. more over more our product ways be to access into for will other pharmacy, to get distribution the sell people through

So a definitely becomes it business. volume

volume pharmacy. today. charge, customers us given an business. for so we PDM moves But as that plays by and move in our are into for And because we're they component we pay-as-you-go from dynamics important the mix are away the those the DME today, direct channels And no get increases traditional far the premium the the for model,

Robbie Marcus

it. we data has should under, the now very Appreciate been to the expect one quick it present major there ATTD Thanks. Are that just label? And in pivotal it. clarification. Got any conferences

Shacey Petrovic

Yes, thanks Robbie.

it's our ATTD had the that. that But were invited evaluating are notified forum and We just great to been with obviously clinical being share We investigators till recently data. we a May. delayed

So thing we're get out a next we there's of most see launch moving the other there. lot us Obviously, year. get appropriate get top FDA to to and And looking of that is it to important just clearance pieces. for forums

So we ruffle don't FDA. feathers want to get the data out ahead of maybe that the at and

provide get looking But we understand, don't options possible. today. as and it soon and we're as to enthusiastic certainly our So specifics out we're there have I at to

Operator

our the go ahead. Please Morgan from you. line question from Thank comes Stanley. Lewis David next Actually of

David Lewis

we of XXXX next should into Thanks of year next afternoon. impacting as fair we margin considerations the wonder in launching of the starts, course I a we about if level that terms talked new about sort about here. early anything XXXX. think of could for sort think which Good bleed COVID helpful amount patients could mix Is any models all patients about taking about be you've that modeling? then of part new year considerations be questions when certain starts, year we this there business OmniPod of Wayde, thinking X is think year, high margins, as and at

Wayde McMillan

QX. a our strong and we're into the percentage a pretty I few U.S. checked guide, your off the from ones, this with high pretty ones up At And significant just our start off progression, the COVID harder QX for only got that a is major because you we've predict us, We're Yes, a think, to that's beginning step one of estimate points of in seen was expecting this David. estimate. big let's we've of improvement the end

give really we'll get and QX XXXX. always does pretty up we're about guide We the And our give the know So is we're obviously And through it at If then we hit our that's QX after set our in call. U.S. strong unknown. how get more in anticipating recovery us guide. there, to XXXX COVID we

have U.S. the we'll international, the better in more part and more much of for so, the what at feel, think, seeing we're like lockdowns early here already And XXXX I U.S. least will the a Outside look quarter. in

range we've again, the thing. a much far feel it makes it provided comfortable, more but that's we're challenging so for we so year – And we'll next international, that be in

So, with, a COVID, obviously mark. question that's

other be OmniPod drivers that will year. until second material so year X, release see a mentioned the comes of – For one and of market first we that half limited impact the the the half you our won't

think half we I XX. can modeling the David, a the were XX the from in manufacturing stood about the for third And just under OmniPod to same up us announced standpoint, X, year. China. So do that programs party would recently report XX that your and starting a very QX, of I think to ramp think Gross to for going. happy to we about another of question, second We have year. lot We up sets plant margins, next we've in really

our get lines product. working to there first we're two sellable And so

set margin on we're inside the And gross got that things up capacity the And to. happening increase same short-term that so of a they we we've U.S. number, at but if designed are to a basis up all us ramping so get need of lot time can we

ramp, the on So that volume I year. think the end, XX% in we're just low to we range at and on high depending could squarely could end. at XX% be Depending be next for as we easily we how the fast but

continue pricing questions, that pardon us the think in We're we'll at and mark channel. pharmacy standpoint, to I X up moving XX% is, be business, that direct still one the just whether what pharmacy DME from price is when margin we'll call. price from we'll side And the standpoint earnings gross done So DASH. ramping a get guidance few customers OmniPod premium our parity in of the From for mix a modeling there clarify look range. the QX – to XX% to from Dave, have right there's a into The not thing our or there? question we'll so or that's benefit see open mix me, to and we less our and a

David Lewis

helpful. Okay. Super

Just one question more Shacey. for

assuming, about for think then momentum I And kind quarter, there's of of because things impacting I'm in the different that probably just third X and So slowdown Wayde U.S. about always you've third of underlying about sort slowed the of calls, as quarter you and the peak Type to the well. talked about quarter, U.S. change patients start fourth in these just OmniPod X the the you some Shacey, as MDI, COVID fundamentals. guided momentum year no new talked reflects couple last you've in talk next

curious, a it it the you conversion X between for OmniPod two? business, business? so which market driver the significant conversions, is in impact X next think I'm Type part or the share, the opportunity year, which the not about kind been much. the you you Thanks X more has accelerates, of do most, just actually think of what As the Type of mounted necessarily of MDI underappreciated the is

Wayde McMillan

Sure.

that So a in sequential it I the was problem QX new our then David you the quarter. you can significantly mentioned, I quarter see had growth on growth customer from lower mean, right, and that out big rates. we can start will you're QX in we we is where four for QX year. the adding that the business And to And and and that of four. next customer that's into annualize live new one starts with start starts quarters. three

well product so building as as into model has So, come much four on the innovations, the end around Type the guidance. around to the to quarters pharmacy, well goal business of end our made with strategies factored things training, to and all inside compounded that's really I can have commercial of mentioned momentum in that's with business, process. and as to other is happening. the and we've as obviously the perspective the the because investments wanted including I of customer momentum what as just there's out as pandemic we we and our salesforce it think But our new business side X Shacey give the And our three here impact virtual share much

there's compounding so this many for good offsetting so And start us. that customer things is just new

looks in year. Come QX the don't be to to have annualize the QX impact to QX so yet stronger. we Is what don't And going But other we then I really get and QX to what is until here. really next out we build pandemic QX it's our that see know the like. momentum the job trough? tough out side

Shacey Petrovic

a when on forward your guess a looking data on XXXX. get converting. what's integration. MDI most happening would it in, are because that we're indicate has Because at nobody sort tubes. I they X, our that over the question you OmniPod Dexcom about the think do, one I think, pump today, David, chooses, users And it I tubed question. choose least seeing And answer if in about to because it They it's a OmniPod excited great has nobody of chooses

the constant OmniPod check that believe we get easier other should a box And we phone will about like and conversions get when And data obviously plus and much we larger differentiated, things use. that be a get significantly X be I've access of we we we much larger – spoken a already should one. think about. large When today key all that check box, to control, very MDI can to percent so like features

So into that the capital some a locked Because are probably about of the folks equipment four-year those if biggest to opportunity. me those you most is think model, contract. of folks,

in think will and for with be with happens see a today. familiar an less area patients terms very the appealing adoption what them OmniPod from get of we that where that's differentiated integration a And to But we little in And to know for check is automation attracted very, very that's going area it'll are up. we interesting of OmniPod that of users come because less population, that I XX% to X. we’re X. be sure What MDI so box Dexcom, when going be to and And product.

Operator

Wells of line next show I Fargo. go from Larry you. the our Thank question Please from ahead. comes Biegelsen

Larry Biegelsen

international, of Thanks One taking guys. Thanks on OmniPod the course X. one question. on, for

that I follow-up in think, guys remarks. high How And behind far past, about five the U.S.? still are range. markets teens, new heard low outside launch OmniPod I the Is X, one I international being the markets you compared to in Which intact? have is new it growth you XXXX? planning in to in talked U.S. XX% the prepared the So have

Shacey Petrovic

and the the slower of than growth. Great. pandemic in into expectations we're United there's Maybe in would I'll of in been that international that simply parts business States. in particularly there's just ask nothing fundamental a long-term bit change But for Wayde to the other It's insight little the midst our Europe, that recovery, particularly that expectations of the business. a give overall for world a and

very expansion We the over significant the that in it's in the remain time, we're us long-term. And coming our in So market give over XXXX. our mentioned why adds five on markets. over starting my we really years. I to earnest strategy this addressable didn't bullish remarks And expansion early

we'll lay Belgium. the So we those We them. as into out checked off box you in get did quarter for one this enter

will entered. best those one actually And as launches we we occurred. have So enter you of know these that let markets, the

Larry Biegelsen

Thank you.

Shacey Petrovic

also – X about Larry then OmniPod asked And in international. had sorry I

timeline on We that haven't yet. a given

of to that everybody and we OmniPod our Just X, international to is markets. fully to bringing underway work let are to all and know committed European that our markets

Larry Biegelsen

example, anything would from For And number different X, pivotal And ADA typically Thanks guys X for we the from would be aware any or the do pre-pivotal year? larger you. something data, on that? Thank have is that look reason taking the meaningfully you like aware of data pre-pivotal centers, different pivotal that OmniPod that of? there at this the of should OmniPod we should questions. why filed that announce look data we much submitted saw data be the make data

Shacey Petrovic

we Sure, our we don't when Larry. submit, when the or news share simply public we And become cleared. to thanks we're practice notify –

So our that's general practice.

very very but looked the this there. to have data, preview and to Obviously I to to much at pivotal data don't give data want it want OmniPod very, In pivotal point. I just how compares don't the We don't terms into really get strong insight excited out insight the are we there, of offer it. pre

Larry Biegelsen

you. Thank Understood.

Shacey Petrovic

Larry. Thanks

Operator

Jeff next Please ahead. go from question Johnson Yes, comes from Baird. the our line of

Jeff Johnson

afternoon, access on potentially a that Good pricing couple you probably try that. were settled faster than that to in out after counts you. going point to just across there the more at to pricing broadly premium and more OmniPod this it kind X thoughts go Wayde a of Thank of and guys. you was questions. year. thought next Maybe clarifying I just for mentioned get

about is there a you that all could a region to that? how five or for think get happening just, So maybe premium

Wayde McMillan

different There's a systems getting the U.S. opportunities that AID us in for for And is in marketplace. Jeff. consideration take major lot we're to certainly still current are other us environment said, across into the particular. it's of our like it question for But we the sold as a that customers as Yes, you a fast consideration us, in, possible.

so And through place, pricing parity built Having infrastructure process the work there a and faster. we opportunity if for us put up said we've get now wholesalers up built significant at there to to in we've a through go distributors, teams, long even and up lot that a that, DASH. there's of learned the access and is our we've our ramp we

And a us. really customers, many standpoint, of still but to of Jeff get on the for to just approach one is customers. question are so we into customer the very just it premium, want Lots and obviously to current depends and a there it how benefits market. as our a new really benefits it compelling hands from price

for off jump still is So us. yes, a that one

Jeff Johnson

probably parity last in it even XQ par what was year-over-year, were was me obviously on maybe in seems which create dramatically be year the on stronger, they not pre-COVID are maybe confuse When the new the starts the kind but U.S. down Is the o-U.S. and what to to is quarter, I that that patients marginally this starts just like put the then were with Okay, down. cumulative they expects. patient closed be new it guide your And way seem XQ, XXXX, the relative good talked great. to quarter basis fair you data U.S. an to way a simplistically I XQ year. times in basis, it your X% little patient absolute does almost to blender, starts at of the new investors all to seems in an were about follow-up math about them or at all itself? absolute XXXX Very points may last that to seems XX% it your a providing, And with lot the take but we and of you a XQ pretty when confusion. on in thinking

Wayde McMillan

just of And this is right, And you’re is we again, challenging. provide I'll highlight Yes. wanted guidance. reasons it to why the one

an to and data So to about provide more it give us points. enough opportunity share

out be of U.S. than stronger against And starts you been headwind And are sounds is put our there, close close. but our QX. QX it's on end really say higher you're is persist the What pretty the lower Jeff, little would been really do The U.S. headwind internationally, to like despite we're tough to a expect more I international going out a And business getting laid low little has again in was a well. comp estimates. there. stated headwind. estimates Those the into little then than than new the QX. experiencing customer And you from we performing

Operator

you. Thank

from Please question line go the of Citibank. next from Joanne comes Our Wuensch ahead.

Joanne Wuensch

get product or how around OmniPod there. a for you launch, could two trying posts incremental just if I'm of X launch, And size but I'm after them you've to just through the think go about, us We've Good six-year-old milestones trying to then looking ramps mile study? next full out already limited front. is And successful walk should any got with we to very – questions. that heard year. I’ll heard that's thanks. DASH head evening all we've and thank What you that population to up put the you the are my taking

Shacey Petrovic

population don't really when know important necessarily they because the have population OmniPod for people Sure, with obviously Not adopt two six-year-olds we population, market. but a of because It's the total the stay of I to Joanne. size that of the us. us. in

on population. where young heavily, young OmniPod heavily technology And focused of a easier children. is the a on pediatric for differentiated active So reasons. a been strategically we've to it's variety It's also always use population much

getting before So and of trial ideally about next we're getting everybody our year. label the expansion excited end in that enrolled clinical

a company, as amount of activity on launch. of OmniPod tremendous there in milestones towards OmniPod we think ramping going X, the about terms the In for is

the we the publication analysis, that We and milestone data, a as clinical and forward. presentation so have of obviously data move will be

systems have and at work for We OmniPod onboarding establishing commercial X. look IT our on to going easy

access market have We work.

affairs, And will which start pharmacy obviously And cross-functional going the to for ton OmniPod then is to going reimbursement have So we medical around in be work et working build have of X. of we we a XX,XXX pages. on to then team channel submission, course cetera. in on XX,XXX the a somewhere

in function way. X some company almost So the is touching in launch individual OmniPod the every

internally progress clearance that we’ll terms manufacturing of the and happening our the our of in is then next lots clinical progress, milestones progress. so our really of the And system. and The commercial data announce thing probably

are it kind all market We a those market know things a it the a will publicly high do the it's the in a release? It's And limited full of so us. you And limited market release. look is of maintained mentioned, for that externally. most is stakes to anticipated we We've always pipeline product innovation release, for products. diabetes

and as limited market And so we that. doing a want of right it to part get release

limited be, be I when seen long objectives XXXX, depends based our end half a meeting of on will feedback. market access, that we release. the for And in ramp, to points a be launch How market limited market our we and will and it into we're upon remains release. that when will So launch first think, manufacturing customer because

Joanne Wuensch

Thank you so much.

Shacey Petrovic

Thanks. Sure.

Operator

Thank you.

Cowen. comes question from go from Blicker of next Our ahead. Please the line Ryan

Ryan Blicker

thanks last of to which similar the quarter. going is U.S. pharmacy, Hi, the to noted greater for than channel pharmacy is U.S. in. pharmacy. me of XX% new volume sticking you XX% Maybe transitions, with starting the adds to

why install can for on any U.S. clear. the slowed bit the volume remains the total additional outlook a for pharmacy pace portion believe the a looking launch long-term large to the to existing the do So quarters? X But color couple you convert a XXXX, to provide over pharmacy? past has catalyst then of increases will quarterly of And you be base your OmniPod

Shacey Petrovic

of expect Ryan, Wayde conversions specific really to And is in channel, numbers I'll let I about access of Hey be OmniPod we that to that is momentum X pharmacy a pharmacy increase. terms would because should maybe going continues very the but a pharmacy do it the terms pharmacy strong in talk catalyst say the channel, be in product.

the we model. demand for committed know technology. lot so there's we are pay-as-you-go to And that to, of committed building the are a And we

Wayde McMillan

Right.

You're correct.

couple number. are than And greater it keeping just points guidance just is Our rounded. of at percentage XX%. We is growing to clarify our a in it

as on just going business to So, customers quarter-to-quarter, new go the as of But given are the probably Shacey primarily DASH quarters we're starts DASH. step-ups grows is said, not pharmacy. well. see And major that majority the our overall in our as

pharmacy grow So we see time. the will continue to volume over

Ryan Blicker

ramping if patient then I That's two-part bodes CGM X X ask time. again the clearly on penetration for opportunity, Type penetration talked about great. pump well the you And could over so follow-up in a Type which population,

Thank that the penetration curious you generated DTP thus have mix you do pump XXXX, being the among far increasing wondering, whether of a gains Type driving acknowledging of not in X early, population, to it's I'd seen your new patients? then more it's believe interest is Type X in of and program know increase evidence patient level least Xs. driven by or at And patient among Just disproportionate or Type your mix any by you. share be really

Shacey Petrovic

in terms Type a see of still there's to and opportunity utilization just as it's CGM massive Ryan. beachhead, go right. get low Xs. penetration, pump pretty We Xs, Thanks, overall sort so a Type in of with Yes,

getting As in X, very challenged perspective. really as access well we in happening see Type Type pumps CGM And said, an you X. but is a from Other maturely are which and going adoption bodes happening, that happens, adoption. for as just pump is trend,

So what's we to access the availability are the very driving channel, and X fortunate the to providing OmniPod population. of model. pharmacy in pay-as-you-go That's Type really be

terms in adoption really and are to discretion position, use of unique a got that our of we product. But So for OmniPod’s know ease technology We the market. helping is CGM know we in in win and channel curve and factor appealing able our be to to we've a terms of drive this. in form that

seeing pumps. so with a conversion in if Xs. testing I And are not pumps messages we're in MDI winning are other we're would we're we bunch primarily of other surprised Type level now seeing right think I the And conversions, of be different And that DTC. winning,

So we to expectations out that X and for the we'll be DTC color into XXXX, for to is as early that said, geared point expect we able at us. a lay population. I we messaging to on what that's this that. be towards to But do as have drive Type give insight give going actually Too able our

Ryan Blicker

Thank you.

Operator

from the line Please question America. next Our comes go Travis of Bank from of Steed ahead.

Travis Steed

for thanks the taking questions. Hi

study you that, [indiscernible] what you to that the from approval. for or began [indiscernible] gain OmniPod hope [indiscernible] on recently Just

Wayde McMillan

some… ask just don’t Why

Shacey Petrovic

you up there. Travis, broke Yes, I’m sorry,

were – fully interference. little So some were didn't we a there you garble,

you question, your If could be repeat would that great.

Travis Steed

was The [indiscernible] that. OmniPod for you for two studies, from [indiscernible] you on sorry approval the that Yes, question gain feasibility need reimbursement coverage? if X will

Shacey Petrovic

Okay, great, feasibility X OmniPod study. X Type

first So of in terms clinical the X. step is for that Type our exploration on OmniPod Xs

step. X label did This eventual an OmniPod you the for with step expansion. is remember a So well. we studies may early X really as feasibility Type in And it's

XX we the get users XX will So, to product. on

algorithm, studies tremendous deliver see, in in performance hypoglycemia, the particularly on when to of the amount algorithm the a just of We tweaking would does range, our work or Remember, segment, expect Remember perform kids we we to OmniPod we X, the that X Type algorithm pre-pivotals. did on for we did best-in-class need feasibility came as great we with to we the time lot we look and lot the early saw population, will had the that tweak algorithm? work a this do had of from algorithm. it of the a with to,

in do out the then that we determine study able path will expansion. to the much we us map be do thing we'll give Feasibility work for seen. And label remains It same have. learnings. what's so the how X be to us Type those And then need population will clinical to may for

isn't really user. X there X and the of terms channel between in distinction Type pharmacy reimbursement, a fortunate Type the we're In

with the And expansion a for the pharmacy Type label in should X. so for way that access channel pave

Travis Steed

through certain and year. in weeks Just were Okay. the versus That's how kind of few there curious to like call that's they spiked is doctors’ how anything geographies? those – the look as different great. And this you out on well-prepared one cases early patients quick last now offices are in as question geographies, earlier

Shacey Petrovic

is Yes, and in I more think more working this effective environment. it's the a good U.S. in point. efficient getting And we mentioned everything

Of for training. of we've talked pathway lot that our virtual lot really training about we've and of a among a built we that confidence patients rolled clinicians the preference our support for out and and course, tools have

as able so And pandemic, more we're patients product. to continue areas experience challenges even onto certain with the the new to bring

said, we're right. guidance Wayde pretty in going the quarter end record in that U.S., a our The indicate feeling of QX. we're would in high good, so And be QX as at to

a little bring France, for particular can great. capabilities more market that's still us. the more fragmented the Outside right are are that see helping a of patients we certainly to our heading more that we into on. built in now. environments it's and So large a bit U.S., UK tools shelter-in-place, France And And environment that and the those continue we is we've challenged have challenged virtual But for us. back ensure to a as

United of is a that outside there in U.S. patients like improved challenged States. more even in the these and in it's still We see not So terms markets. progression certainly starts definitely there of But QX. new doesn't the exist headwind

Travis Steed

Thank you.

Operator

comes go I the last show Raj ahead. from our Denhoy of Jefferies. from line question Please

Briana Warschun

or would house, the manufacturing you how your COGS play of there of [indiscernible] you gross that China? the the in contract quick that other XX%? new the from automated of follow-up things sources long-term high gross This as on in then is a does questions. in on into is versus provide And on as manufacturing could and U.S. mix potential mix? margin for was manufacturing running driver be, hoping in detail end margin Thank XX%, Briana in your target shift upside to is I taking some more into shifts for a just Raj. that And what the Flex China the going through key then

Wayde McMillan

Hi, you've on Briana. touched actually drivers of key a Yes, couple there.

manufacturing that's automated a expensive So fixed for COGS. is And four lot automated for manufacturing because key lines. the question volumes today cost fairly the on lines. And it's us of low product active in plant more designed is a on around a was the mix the lines is two

a than production So today our facility Acton. Flex China lower cost of is our out

you and manufacturing that time, it's gross us as the for that driver more But scale. with over mentioned, that this largest combination lines And be product. designed margins over However, the efficient automated us will in time. single is get of improved is

really pump today. been think with volumes build we as yet, lines put just producing, our China And and building that in we've gross and in investments how new, more those U.S. our product are and not running both here, producing And gross we making significantly help and sellable scale of disposable mass in the up know-how critical margins on we and I in drive we volumes into the well. in do an critical a expertise, have impact producing margins them in mass more manufacturer We've got patch customers product. third-party us not it, those manufacturing, business design. and accumulate China, do to significant, is two this. the And as but the as

or later you. Thank early COGS, And so in XXXX. this those factor either to will start year into our

Operator

you. Thank

Petrovic. turn I at now would conference As time, back there to the are to Shacey this no further questions like

Shacey Petrovic

community acknowledge spent Awareness In our closing, since you. best people both helped and managing let to I life to Thank more Month diabetes the XX And and last diabetes. would Insulet’s living over chronic their with the people lives We've that mission years the advanced XXth brought time, a innovation like Diabetes we've and improve National and of founding. spend with condition. Anniversary their company's clear time

done, deliver about really all proud great we're we have innovations a on to all. as our excited So Thanks we've of evening, mission. very we're And and our come

Operator

day. conference wonderful participation you for a and concludes this Thank today's gentlemen, have and your Ladies call.

all may You disconnect.

Insulet (PODD) 4 Nov 202020 Q3 Earnings call transcript